Assignee
NLS PHARMACEUTICS AG
CH·1 granted patent·10 pending applications·0 citations·filing 2018–2024
Top patents by PatentIndex Score
11 records- 0176US2024108605A1Mazindol combination in the treatment of attention-deficit/hyperactivityNLS PHARMACEUTICS AG·Filed 2023·Application pending·0 cites
- 0266US2022054471A1Phacetoperane for treating of attention deficit hyperactivity disorderNLS PHARMACEUTICS AG·Filed 2021·Application pending·0 cites
- 0363US2021093614A1Mazindol combination in the treatment of attention-deficit/hyperactivityNLS PHARMACEUTICS AG·Filed 2020·Application pending·0 cites
- 0457US2024165034A1Mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)NLS PHARMACEUTICS AG·Filed 2024·Application pending·0 cites
- 0551US2020061044A1Phacetoperane for treating of attention deficit hyperactivity disorderNLS PHARMACEUTICS AG·Filed 2019·Application pending·0 cites
- 0649US2022160639A1Mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)NLS PHARMACEUTICS AG·Filed 2021·Application pending·0 cites
- 0747US2025268859A1Oxafuramine, (1r)-n-ethyl-1-[(2r)-oxolan-2-yl]-2-phenylethanamine, hydrochloride and derivatives thereof for treating alzheimer's disease (ad), vascular dementia, dementia with lewy bodies (dlb), mixed dementia, frontotemporal lobar degeneration (ftld), and parkinson's disease (pd)NLS PHARMACEUTICS AG·Filed 2022·Application pending·0 cites
- 0847US2025049737A1Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)NLS PHARMACEUTICS AG·Filed 2022·Application pending·0 cites
- 0947US2024316023A1Benedin, piperidine, 2-benzhydryl-3-hydroxy-n-methyl-, hydrochloride and derivatives thereof for use in treating kleine-levin syndromeNLS PHARMACEUTICS AG·Filed 2022·Application pending·0 cites
- 1047US2025082598A1Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's diseaseNLS PHARMACEUTICS AG·Filed 2022·Application pending·0 cites
- 1141US11596622B2Mazindol treatment for heroin dependence and substance use disorderNLS PHARMACEUTICS AG·Filed 2018·Granted Mar 7, 2023·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when NLS PHARMACEUTICS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →